Compare VALE & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALE | TEVA |
|---|---|---|
| Founded | 1942 | 1901 |
| Country | Brazil | Israel |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3B | 40.5B |
| IPO Year | 2008 | 1996 |
| Metric | VALE | TEVA |
|---|---|---|
| Price | $11.62 | $42.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 15 |
| Target Price | $15.23 | ★ $49.44 |
| AVG Volume (30 Days) | ★ 35.0M | 6.4M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 5.95% | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | N/A |
| Revenue This Year | $6.76 | N/A |
| Revenue Next Year | N/A | $3.29 |
| P/E Ratio | ★ $29.09 | $2,144.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.96 | $24.01 |
| 52 Week High | $17.94 | $43.34 |
| Indicator | VALE | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 60.55 |
| Support Level | $10.96 | $38.55 |
| Resistance Level | $15.08 | $43.34 |
| Average True Range (ATR) | 0.36 | 1.18 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 41.40 | 78.28 |
Vale is a large global miner and the world's largest producer of iron ore and pellets. In recent years, the company has sold noncore assets such as its fertilizer, coal, and steel operations to concentrate on iron ore, copper, and nickel. Earnings are dominated by its iron ore business. The base metals division is much smaller, consisting of nickel mines and smelters along with copper mines producing copper in concentrate. In 2024, Vale sold a minority 10% stake in its base metals business, likely the first step in separating base metals and iron ore.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.